Statins increase the risk of prostate cancer: A population-based case-control study
The Prostate, 04/13/2011Chang CC et al.
The examination of 388 prostate cancer cases and 1,552 controls in the study shows that ever–use of any statin was associated with a significant increase in prostate cancer risk. Compared with no use of statins, the adjusted odds ratios (ORs) were 1.17 for the group with cumulative dose =<29.44 DDD, 1.59 for the group with cumulative dose between 29.44 DDD and 321.33 DDD, and 1.86 for the group with the highest cumulative dose. There was a significant trend toward increasing prostate cancer risk with increasing cumulative dose.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.